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Kaposi’s sarcoma (KS) is the leading cancer in much of sub-Saharan Africa [1]. HIV has 
resulted in a dramatic increase in KS throughout the region, due to high overlapping 
prevalence of HIV and the etiologic agent of KS, Kaposi’s sarcoma-associated herpesvirus 
(KSHV)[2]. KS is divided into four major categories: classical, iatrogenic, AIDS-related, 
and endemic. Endemic KS is the only KS subtype where a specific immune disturbance is 
not readily apparent [3]. In Malawi, KS is the leading cancer overall accounting for 34% of 
all malignancies recorded in the national cancer registry [4]. In a setting of high KS burden, 
we sought to describe contemporary burden and characteristics of KS in the HIV-positive 
and HIV-negative populations at a national teaching hospital in the capital, Lilongwe.
We analyzed KS cases from May 2014 until May 2016 in the Kamuzu Central Hospital 
Cancer Registry, which involves active registration of cancer cases across all hospital 
departments using standardized data collection forms. We identified 237 overall KS cases, of 
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which 153 were confirmed HIV-positive and 21 confirmed HIV-negative. KS diagnoses were 
histologically confirmed in 39% (92/237) of cases overall, including 33% (50/153) of 
confirmed HIV-positive and 71% (15/21) of confirmed HIV-negative cases. We abstracted 
tumor location and subtype from all confirmed pathology reports.
As expected, KS patients were more commonly males regardless of HIV status (Table 1). 
Age distribution was significantly different based on HIV status (p = 0.012, Fisher’s exact 
test, see Figure, Supplemental Digital Content 1; Graph of KS age distribution within HIV + 
and − by decade). HIV-positive cases primarily presented during young to mid-adulthood 
with 68% of cases occurring between 20 and 49 years of age. By contrast, HIV-negative 
cases were more evenly distributed among age groups. HIV-positive KS tended to present 
with disease at diverse anatomical sites, whereas HIV-negative KS appeared to primarily 
present in the lower extremities (60%). Similarly, lesion descriptions in pathology reports 
suggested greater lesion heterogeneity among HIV-positive patients, with predominantly 
plaque or nodular lesions among HIV-negative patients (73%). Finally, among patients for 
whom the primary treatment modality was recorded, 49% of HIV-positive patients and 33% 
of HIV-negative patients received chemotherapy. Of note, radiotherapy is not available in 
Malawi.
These findings suggest that despite high HIV prevalence in Malawi, HIV-negative endemic 
KS represents at least 9% of contemporary KS burden at a national teaching hospital, with 
possible differences in presenting characteristics between HIV-positive and HIV-negative 
patients. Despite major investments and research programs in the region focused on AIDS-
related KS, endemic KS has received relatively little attention. At our center, endemic KS 
appeared to occur at both younger and older ages compared to HIV-positive KS. Lifelong 
KSHV infection in sub-Saharan Africa is often acquired in childhood through salivary and 
breast milk transmission, although KSHV may also be acquired in adulthood. Subsequent 
infection with HIV during adulthood abruptly alters host immune function allowing KS 
development, accounting for high KS burden in the HIV positive population between ages 
20–49 years. In the absence of HIV, precipitating co-factors of endemic KS remain unclear 
and may be associated with volcanic soils, African natural products, and genetic 
predisposition [5–7].
As antiretroviral therapy (ART) scale-up continues in Malawi, which began in 2004 with 
ART coverage now reaching 67% of eligible HIV-positive patients [8], incidence of AIDS-
associated KS is anticipated to decline. These trends, coupled with demographic shifts in 
sub-Saharan Africa with aging of populations overall, may result in higher proportions of 
KS in older individuals and relatively constant burden among children, regardless of HIV 
status. At our center, many of these patients had severe enough disease to require treatment 
with chemotherapy at a tertiary referral oncology clinic. This may become increasingly 
important, since treatment of older patients with cytotoxic therapy is challenging in 
resource-limited settings without appropriate supportive care infrastructure. Novel treatment 
paradigms, including greater application of non-cytotoxic therapies and local treatments for 
limited-stage disease, may therefore be needed. Finally, questions remain as to how endemic 
KS evolves from KSHV infection. Studies in the US and Malawi suggest the presence of at 
least two subtypes of KS on the basis of gene expression profiling [9, 10]. Understanding 
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precipitating and viral factors in HIV-negative populations may help guide therapy 
development and prevention efforts.
In conclusion, embedded efforts to better understand endemic KS are needed within larger 
regional initiatives focused on AIDS-related KS. If successful, such efforts have potential to 
guide prevention and treatment strategies which can better address overall KS burden in 
Malawi and comparable settings, as ART scale-up continues and populations continue to 
age.
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Table 1
KS Demographics at Kamuzu Central Hospital
Demographics were constructed from KS cases recorded from May 2014 until May 2016 in a hospital-based 
cancer registry at Kamuzu Central Hospital. Tumor location and subtype were gleaned from pathology reports 
from collected cases, when available.
HIV− (N=21) HIV+ (N=153)
Age
 < = 19 5 24% 11 7%
 20–49 7 33% 104 68%
 > = 50 7 33% 20 13%
 Unknown 2 10% 18 12%
Sex
 Male 16 76% 103 67%
 Female 5 24% 50 33%
Tumor site
 Lower extremity 9 60% 17 34%
 Trunk 2 13% 12 24%
 Upper extremity 2 13% 2 4%
 Head/Neck 0 0% 5 10%
 Lymph Node 1 7% 12 24%
 Other 1 7% 2 4%
Tumor Subtype
 Lymphadenomatous 1 7% 12 24%
 Patch 0 0% 3 6%
 Plaque 3 20% 8 16%
 Nodular 8 53% 11 22%
 Visceral 0 0% 2 4%
 Unclear 3 20% 14 28%
Treatment Received
 Surgical Resection 1 5% 0 0%
 Chemotherapy 7 33% 75 49%
 Unknown 13 62% 78 51%
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